메뉴 건너뛰기




Volumn 35, Issue 7, 2016, Pages 1659-1668

Withdrawal of biologic agents in rheumatoid arthritis: a systematic review and meta-analysis

Author keywords

Antirheumatic agents; Remission; Rheumatoid arthritis; Withdrawal; Withholding treatment

Indexed keywords

BIOLOGICAL PRODUCT; ANTIRHEUMATIC AGENT; INFLIXIMAB; METHOTREXATE;

EID: 84964310736     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-016-3285-y     Document Type: Article
Times cited : (23)

References (46)
  • 2
    • 84893721202 scopus 로고    scopus 로고
    • Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis
    • COI: 1:CAS:528:DC%2BC2cXmsFWku7o%3D, PID: 24399231
    • Nam JL, Ramiro S, Gaujoux-Viala C, Takase K, Leon-Garcia M, Emery P, Gossec L, Landewe R, Smolen JS, Buch MH (2014) Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 73(3):516–528. doi:10.1136/annrheumdis-2013-204577
    • (2014) Ann Rheum Dis , vol.73 , Issue.3 , pp. 516-528
    • Nam, J.L.1    Ramiro, S.2    Gaujoux-Viala, C.3    Takase, K.4    Leon-Garcia, M.5    Emery, P.6    Gossec, L.7    Landewe, R.8    Smolen, J.S.9    Buch, M.H.10
  • 3
    • 84893803131 scopus 로고    scopus 로고
    • Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
    • COI: 1:CAS:528:DC%2BC2cXmsFWku7g%3D, PID: 24401994
    • Ramiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, Gossec L, van der Heijde D, Winthrop K, Landewe R (2014) Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 73(3):529–535. doi:10.1136/annrheumdis-2013-204575
    • (2014) Ann Rheum Dis , vol.73 , Issue.3 , pp. 529-535
    • Ramiro, S.1    Gaujoux-Viala, C.2    Nam, J.L.3    Smolen, J.S.4    Buch, M.5    Gossec, L.6    van der Heijde, D.7    Winthrop, K.8    Landewe, R.9
  • 4
    • 84921799551 scopus 로고    scopus 로고
    • Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspective
    • PID: 25653505
    • Bolge SC, Goren A, Tandon N (2015) Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspective. Patient Prefer Adherence 9:121–131. doi:10.2147/ppa.s70834
    • (2015) Patient Prefer Adherence , vol.9 , pp. 121-131
    • Bolge, S.C.1    Goren, A.2    Tandon, N.3
  • 5
    • 84870257368 scopus 로고    scopus 로고
    • Do we need guidelines to stop as well as to start biological therapies for rheumatoid arthritis?
    • PID: 23073206
    • van den Broek M, Lems WF, Allaart CF (2012) Do we need guidelines to stop as well as to start biological therapies for rheumatoid arthritis? Clin Exp Rheumatol 30(4 Suppl 73):S21–S26
    • (2012) Clin Exp Rheumatol , vol.30 , pp. S21-S26
    • van den Broek, M.1    Lems, W.F.2    Allaart, C.F.3
  • 6
    • 84929834401 scopus 로고    scopus 로고
    • Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under real-world settings: a systematic review
    • COI: 1:CAS:528:DC%2BC2MXhvFCit78%3D, PID: 25638015
    • Ferriols-Lisart R, Ferriols-Lisart F (2015) Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under real-world settings: a systematic review. Rheumatol Int 35(7):1193–1210. doi:10.1007/s00296-015-3222-4
    • (2015) Rheumatol Int , vol.35 , Issue.7 , pp. 1193-1210
    • Ferriols-Lisart, R.1    Ferriols-Lisart, F.2
  • 7
    • 84890312619 scopus 로고    scopus 로고
    • Is it possible to withdraw biologics from therapy in rheumatoid arthritis?
    • PID: 24290736
    • Tanaka Y, Hirata S (2013) Is it possible to withdraw biologics from therapy in rheumatoid arthritis? Clin Ther 35(12):2028–2035. doi:10.1016/j.clinthera.2013.10.008
    • (2013) Clin Ther , vol.35 , Issue.12 , pp. 2028-2035
    • Tanaka, Y.1    Hirata, S.2
  • 8
    • 77957265767 scopus 로고    scopus 로고
    • Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis
    • PID: 19224904
    • O’Mahony R, Richards A, Deighton C, Scott D (2009) Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 69(10):1823–1826. doi:10.1136/ard.2008.105577
    • (2009) Ann Rheum Dis , vol.69 , Issue.10 , pp. 1823-1826
    • O’Mahony, R.1    Richards, A.2    Deighton, C.3    Scott, D.4
  • 13
    • 84889683898 scopus 로고    scopus 로고
    • Proposal for a new nomenclature of disease-modifying antirheumatic drugs
    • PID: 24072562
    • Smolen JS, van der Heijde D, Machold KP, Aletaha D, Landewe R (2013) Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis 73(1):3–5. doi:10.1136/annrheumdis-2013-204317
    • (2013) Ann Rheum Dis , vol.73 , Issue.1 , pp. 3-5
    • Smolen, J.S.1    van der Heijde, D.2    Machold, K.P.3    Aletaha, D.4    Landewe, R.5
  • 14
    • 85100415918 scopus 로고    scopus 로고
    • Higgins J, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Collab. Accessed Apr 14 2011
    • Higgins J, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Collab. www.cochrane-handbook.org. Accessed Apr 14 2011
  • 15
    • 77951748802 scopus 로고    scopus 로고
    • What outcomes from pharmacologic treatments are important to people with rheumatoid arthritis? Creating the basis of a patient core set
    • COI: 1:STN:280:DC%2BC3czivV2ksg%3D%3D
    • Sanderson T, Morris M, Calnan M, Richards P, Hewlett S (2010) What outcomes from pharmacologic treatments are important to people with rheumatoid arthritis? Creating the basis of a patient core set. Arthritis Care Res (Hoboken) 62(5):640–646. doi:10.1002/acr.20034
    • (2010) Arthritis Care Res (Hoboken) , vol.62 , Issue.5 , pp. 640-646
    • Sanderson, T.1    Morris, M.2    Calnan, M.3    Richards, P.4    Hewlett, S.5
  • 19
    • 84975601076 scopus 로고    scopus 로고
    • Assessing Withdrawal of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis (ARCTIC REWIND). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). (2014). Accessed Sep 22 2014
    • Assessing Withdrawal of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis (ARCTIC REWIND). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). (2014). http://clinicaltrials.gov/show/NCT01881308. Accessed Sep 22 2014
  • 20
    • 84975630879 scopus 로고    scopus 로고
    • Cimzia treatment in rheumatoid arthritis: randomizing to stop versus continue disease-modifying anti-rheumatic drug(s). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). (2013). Accessed Sep 22 2014
    • Cimzia treatment in rheumatoid arthritis: randomizing to stop versus continue disease-modifying anti-rheumatic drug(s). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). (2013). http://clinicaltrials.gov/show/NCT01489384. Accessed Sep 22 2014
  • 21
    • 84975629247 scopus 로고    scopus 로고
    • Tapering and withdrawal of Methotrexate (MTX) or Tocilizumab (TCZ), after achievement of RA remission in concomitant use of MTX and TCZ, a randomized control study. (2015) UMIN-CTR Clinical Trial.
    • Tapering and withdrawal of Methotrexate (MTX) or Tocilizumab (TCZ), after achievement of RA remission in concomitant use of MTX and TCZ, a randomized control study. (2015) UMIN-CTR Clinical Trial. https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&language=E&recptno=R000020368.
  • 22
    • 84975601067 scopus 로고    scopus 로고
    • A study to investigate the ability of GSK706769 to maintain clinical remission after withdrawal of Enbrel in rheumatoid arthritis patients. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). (2012). Accessed Sep 22 2014
    • A study to investigate the ability of GSK706769 to maintain clinical remission after withdrawal of Enbrel in rheumatoid arthritis patients. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). (2012). http://clinicaltrials.gov/show/NCT00979771. Accessed Sep 22 2014
  • 23
    • 84892843036 scopus 로고    scopus 로고
    • Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial
    • COI: 1:CAS:528:DC%2BC3sXhslSlsL%2FO, PID: 24168956
    • Smolen JS, Emery P, Fleischmann R, van Vollenhoven RF, Pavelka K, Durez P, Guérette B, Kupper H, Redden L, Arora V, Kavanaugh A (2014) Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet 383(9914):321–332. doi:10.1016/S0140-6736(13)61751-1
    • (2014) Lancet , vol.383 , Issue.9914 , pp. 321-332
    • Smolen, J.S.1    Emery, P.2    Fleischmann, R.3    van Vollenhoven, R.F.4    Pavelka, K.5    Durez, P.6    Guérette, B.7    Kupper, H.8    Redden, L.9    Arora, V.10    Kavanaugh, A.11
  • 24
    • 84874983369 scopus 로고    scopus 로고
    • Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial
    • COI: 1:CAS:528:DC%2BC3sXhtFKqs74%3D, PID: 23332236
    • Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, Miranda P, Park MC, Pavelka K, Pedersen R, Szumski A, Hammond C, Koenig AS, Vlahos B (2013) Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 381(9870):918–929. doi:10.1016/S0140-6736(12)61811-X
    • (2013) Lancet , vol.381 , Issue.9870 , pp. 918-929
    • Smolen, J.S.1    Nash, P.2    Durez, P.3    Hall, S.4    Ilivanova, E.5    Irazoque-Palazuelos, F.6    Miranda, P.7    Park, M.C.8    Pavelka, K.9    Pedersen, R.10    Szumski, A.11    Hammond, C.12    Koenig, A.S.13    Vlahos, B.14
  • 27
    • 84988447917 scopus 로고    scopus 로고
    • A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission
    • PID: 26819752
    • Chatzidionysiou K, Turesson C, Teleman A, Knight A, Lindqvist E, Larsson P, Coster L, Forslind K, van Vollenhoven R, Heimburger M (2016) A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open 2(1), e000133. doi:10.1136/rmdopen-2015-000133
    • (2016) RMD Open , vol.2 , Issue.1
    • Chatzidionysiou, K.1    Turesson, C.2    Teleman, A.3    Knight, A.4    Lindqvist, E.5    Larsson, P.6    Coster, L.7    Forslind, K.8    van Vollenhoven, R.9    Heimburger, M.10
  • 29
    • 84946593707 scopus 로고    scopus 로고
    • Flare rate in patients with rheumatoid arthritis in low disease activity or remission when tapering or stopping synthetic or biologic DMARD: a systematic review
    • PID: 26428204
    • Kuijper TM, Lamers-Karnebeek FB, Jacobs JW, Hazes JM, Luime JJ (2015) Flare rate in patients with rheumatoid arthritis in low disease activity or remission when tapering or stopping synthetic or biologic DMARD: a systematic review. J Rheumatol 42(11):2012–2022. doi:10.3899/jrheum.141520
    • (2015) J Rheumatol , vol.42 , Issue.11 , pp. 2012-2022
    • Kuijper, T.M.1    Lamers-Karnebeek, F.B.2    Jacobs, J.W.3    Hazes, J.M.4    Luime, J.J.5
  • 31
    • 79959795633 scopus 로고    scopus 로고
    • Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study
    • PID: 21515916
    • van den Broek M, Klarenbeek NB, Dirven L, van Schaardenburg D, Hulsmans HM, Kerstens PJ, Huizinga TW, Dijkmans BA, Allaart CF (2011) Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Ann Rheum Dis 70(8):1389–1394. doi:10.1136/ard.2010.147751
    • (2011) Ann Rheum Dis , vol.70 , Issue.8 , pp. 1389-1394
    • van den Broek, M.1    Klarenbeek, N.B.2    Dirven, L.3    van Schaardenburg, D.4    Hulsmans, H.M.5    Kerstens, P.J.6    Huizinga, T.W.7    Dijkmans, B.A.8    Allaart, C.F.9
  • 32
    • 84873115118 scopus 로고    scopus 로고
    • A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non-inferiority study of first TNF inhibitor use: outcomes over 2 years
    • Jobanputra P, Maggs F, Deeming A, Carruthers D, Rankin E, Jordan AC, Faizal A, Goddard C, Pugh M, Bowman SJ, Brailsford S, Nightingale P (2012) A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non-inferiority study of first TNF inhibitor use: outcomes over 2 years. BMJ Open 2 (6). doi:10.1136/bmjopen-2012-001395
    • (2012) BMJ Open , vol.2 , Issue.6
    • Jobanputra, P.1    Maggs, F.2    Deeming, A.3    Carruthers, D.4    Rankin, E.5    Jordan, A.C.6    Faizal, A.7    Goddard, C.8    Pugh, M.9    Bowman, S.J.10    Brailsford, S.11    Nightingale, P.12
  • 34
    • 84955198252 scopus 로고    scopus 로고
    • Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study)
    • PID: 26103979
    • Fautrel B, Pham T, Alfaiate T, Gandjbakhch F, Foltz V, Morel J, Dernis E, Gaudin P, Brocq O, Solau-Gervais E, Berthelot JM, Balblanc JC, Mariette X, Tubach F (2016) Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study). Ann Rheum Dis 75(1):59–67. doi:10.1136/annrheumdis-2014-206696
    • (2016) Ann Rheum Dis , vol.75 , Issue.1 , pp. 59-67
    • Fautrel, B.1    Pham, T.2    Alfaiate, T.3    Gandjbakhch, F.4    Foltz, V.5    Morel, J.6    Dernis, E.7    Gaudin, P.8    Brocq, O.9    Solau-Gervais, E.10    Berthelot, J.M.11    Balblanc, J.C.12    Mariette, X.13    Tubach, F.14
  • 36
    • 84928023549 scopus 로고    scopus 로고
    • Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial
    • PID: 25858265
    • van Herwaarden N, van der Maas A, Minten MJ, van den Hoogen FH, Kievit W, van Vollenhoven RF, Bijlsma JW, van den Bemt BJ, den Broeder AA (2015) Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. BMJ 350:h1389. doi:10.1136/bmj.h1389
    • (2015) BMJ , vol.350 , pp. h1389
    • van Herwaarden, N.1    van der Maas, A.2    Minten, M.J.3    van den Hoogen, F.H.4    Kievit, W.5    van Vollenhoven, R.F.6    Bijlsma, J.W.7    van den Bemt, B.J.8    den Broeder, A.A.9
  • 38
    • 84918571233 scopus 로고    scopus 로고
    • Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period
    • COI: 1:CAS:528:DC%2BC2MXitFCiu74%3D, PID: 25367713
    • Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Barre E, Karyekar CS, Wong DA, Huizinga TW (2015) Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis 74(1):19–26. doi:10.1136/annrheumdis-2014-206106
    • (2015) Ann Rheum Dis , vol.74 , Issue.1 , pp. 19-26
    • Emery, P.1    Burmester, G.R.2    Bykerk, V.P.3    Combe, B.G.4    Furst, D.E.5    Barre, E.6    Karyekar, C.S.7    Wong, D.A.8    Huizinga, T.W.9
  • 40
    • 84892899808 scopus 로고    scopus 로고
    • Financial conflicts of interest and reporting bias regarding the association between sugar-sweetened beverages and weight gain: a systematic review of systematic reviews
    • Bes-Rastrollo M, Schulze MB, Ruiz-Canela M, Martinez-Gonzalez MA (2013) Financial conflicts of interest and reporting bias regarding the association between sugar-sweetened beverages and weight gain: a systematic review of systematic reviews. PLoS Med 10 (12):e1001578; dicsussion e1001578. doi:10.1371/journal.pmed.1001578
    • (2013) PLoS Med 10 (12):e1001578; dicsussion , vol.e1001578
    • Bes-Rastrollo, M.1    Schulze, M.B.2    Ruiz-Canela, M.3    Martinez-Gonzalez, M.A.4
  • 41
    • 84902545997 scopus 로고    scopus 로고
    • The comparison of effects of biologic agents on rheumatoid arthritis damage progression is biased by period of enrollment: data from a systematic review and meta-analysis
    • COI: 1:CAS:528:DC%2BC3sXitVWjtrbK, PID: 24332807
    • Favalli EG, Pregnolato F, Biggioggero M, Meroni PL (2014) The comparison of effects of biologic agents on rheumatoid arthritis damage progression is biased by period of enrollment: data from a systematic review and meta-analysis. Semin Arthritis Rheum 43(6):730–737. doi:10.1016/j.semarthrit.2013.11.006
    • (2014) Semin Arthritis Rheum , vol.43 , Issue.6 , pp. 730-737
    • Favalli, E.G.1    Pregnolato, F.2    Biggioggero, M.3    Meroni, P.L.4
  • 42
    • 84918578141 scopus 로고    scopus 로고
    • The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region
    • PID: 25342759
    • van Schie KA, Hart MH, de Groot ER, Kruithof S, Aarden LA, Wolbink GJ, Rispens T (2015) The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis 74(1):311–314. doi:10.1136/annrheumdis-2014-206237
    • (2015) Ann Rheum Dis , vol.74 , Issue.1 , pp. 311-314
    • van Schie, K.A.1    Hart, M.H.2    de Groot, E.R.3    Kruithof, S.4    Aarden, L.A.5    Wolbink, G.J.6    Rispens, T.7
  • 43
    • 67649755653 scopus 로고    scopus 로고
    • Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis
    • COI: 1:CAS:528:DC%2BC3cXht1Clur7P
    • Brocq O, Millasseau E, Albert C, Grisot C, Flory P, Roux CH, Euller-Ziegler L (2009) Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint, Bone, Spine: Rev Rhum 76(4):350–355. doi:10.1016/j.jbspin.2008.11.009
    • (2009) Joint, Bone, Spine: Rev Rhum , vol.76 , Issue.4 , pp. 350-355
    • Brocq, O.1    Millasseau, E.2    Albert, C.3    Grisot, C.4    Flory, P.5    Roux, C.H.6    Euller-Ziegler, L.7
  • 44
    • 84885767488 scopus 로고    scopus 로고
    • The BeSt way of withdrawing biologic agents
    • COI: 1:STN:280:DC%2BC2c7ivFWguw%3D%3D, PID: 24129130
    • Allaart CF, Lems WF, Huizinga TW (2013) The BeSt way of withdrawing biologic agents. Clin Exp Rheumatol 31(4 Suppl 78):S14–S18
    • (2013) Clin Exp Rheumatol , vol.31 , pp. S14-S18
    • Allaart, C.F.1    Lems, W.F.2    Huizinga, T.W.3
  • 45
    • 84975641707 scopus 로고    scopus 로고
    • Ultrasonography as predictor for flare in rheumatoid arthritis patients with low disease activity: nine month results from POET-US-study
    • Lamers-Karnebeek FBG, Jansen T, Riel P, Luime J, Jacobs J (2015) Ultrasonography as predictor for flare in rheumatoid arthritis patients with low disease activity: nine month results from POET-US-study. Ann Rheum Dis 74(Suppl 2):140. doi:10.1136/annrheumdis2015eular.5185
    • (2015) Ann Rheum Dis , vol.74 , pp. 140
    • Lamers-Karnebeek, F.B.G.1    Jansen, T.2    Riel, P.3    Luime, J.4    Jacobs, J.5
  • 46
    • 84956656967 scopus 로고    scopus 로고
    • Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study
    • PID: 26764260
    • Kievit W, van Herwaarden N, van den Hoogen FH, van Vollenhoven RF, Bijlsma JW, van den Bemt BJ, van der Maas A, den Broeder AA (2016) Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Ann Rheum Dis. doi:10.1136/annrheumdis-2015-208317
    • (2016) Ann Rheum Dis
    • Kievit, W.1    van Herwaarden, N.2    van den Hoogen, F.H.3    van Vollenhoven, R.F.4    Bijlsma, J.W.5    van den Bemt, B.J.6    van der Maas, A.7    den Broeder, A.A.8


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.